Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Investor's Business Daily on MSN34m
Allurion Catapults 200% On Its Plans To Outdo Eli Lilly, Novo Nordisk
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
Interaksyon on MSN40m
Pfizer going ‘all in’ on obesity drug development, CEO Bourla says
U.S. drugmaker Pfizer PFE.N is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...